share_log

Needham Reiterates Buy on Conmed, Maintains $107 Price Target

Benzinga ·  May 6 05:49

Needham analyst Mike Matson reiterates Conmed (NYSE:CNMD) with a Buy and maintains $107 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment